Category: Diabetes
Medtronic Diabetes Business Separation
Medtronic Diabetes business separation is a plan to spin off its $2.8B diabetes unit into a separate public company by 2026. Discover what this means for digital diabetes care, CGM innovation, and i... Read More
Telemedicine in Diabetes Care: Is It the Future?
Telemedicine in diabetes care is rapidly transforming how patients manage chronic conditions like Type 1 and Type 2 diabetes. From continuous glucose monitoring (CGM) to app-based coaching and virtual... Read More
U.S. Diabetes Market Size And Growth: What Investors Need to Know in 2025
The U.S. diabetes market is undergoing a rapid transformation, fueled by technological innovation, rising obesity rates, and growing demand for smarter, more personalized treatment options. Valued at ... Read More
Non-Injectable Diabetes Medications and Treatments in 2025
For decades, injectable insulin and GLP-1 receptor agonists have been the gold standard in diabetes management. But for millions of patients, daily injections are painful, inconvenient, and often lead... Read More
The Ultimate US Diabetes Market Overview in 2025: Trends, Innovations, and Market Growth
The Ultimate US Diabetes Market Overview explores the current state of the US diabetes market in the year 2025, breaking down key industry trends, major players, and technological innovations that are... Read More
Top 5 Diabetes Drugs in 2025
Diabetes treatment is evolving rapidly, with pharmaceutical companies racing to develop more effective therapies. The combined cost of diagnosed diabetes and prediabetes in the United States amounts t... Read More
Flash Glucose Monitoring Continues to Grow Despite the Presence of CGM Industry
The continuous glucose monitoring (CGM) market has experienced strong but slowing growth in the U.S. blood glucose monitoring sector. Valued at over $6 billion in 2024, the market is only projected to... Read More
Ozempic FDA-Approved to Lower Kidney Disease Risk in Diabetic Patients
Earlier last week, the US Food and Drug Administration (FDA) approved Novo Nordisk to utilize their already successful semaglutide drug, Ozempic, to reduce the risk of kidney failure and kidney diseas... Read More
